Drugs / L-dopa
L-dopa
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04244058 | Sep 2020 → May 2023 | cognitive disorder, traumatic brain injury | Weill Medical College of Cornell University | Suspended | No outcome recorded Stop: Enrollment |
| Phase 12 trials | ||||||
| Phase 1 | NCT03754062 | Jun 2017 → Sep 2019 | — | King's College London | Completed | No outcome recorded |
| Phase 1 | NCT01437293 | Aug 2010 → Apr 2012 | cocaine abuse | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04558112 | Feb 2021 → Dec 2023 overdue | post-traumatic stress disorder | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT04469959 | Feb 2021 → Apr 2026 | cognitive disorder, major depressive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03541356 | May 2018 → Jun 2019 | Parkinson disease | Impel Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03243552 | Jun 2017 → Dec 2023 | autism spectrum disorder 1 | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 2 | NCT02347059 | Jan 2015 → Aug 2016 | Parkinson disease | University of Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT00200447 | Mar → Sep 2004 | Parkinson disease | Molecular NeuroImaging | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04990284 | Nov 2021 → Apr 2023 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07614126 | Apr → Dec 2026 expected | CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy | University Hospital, Montpellier | Recruiting | No outcome recorded |
| — | NCT05909267 | Jul 2023 → Jul 2026 overdue | major depressive disorder | Charite University, Berlin, Germany | Recruiting | No outcome recorded |
| — | NCT03891095 | Dec 2018 → Jan 2019 | — | Beijing Normal University | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 2 | NCT07370532 Comparator | Jan 2026 → Nov 2027 expected | Parkinson disease | Ihab Elsayed Hassan | Recruiting | No outcome recorded |
| Phase 2 | NCT01092065 Background | Mar 2010 → Jul 2011 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00537017 Background | Nov 2007 → Nov 2009 | Parkinson disease, movement disorder, neurodegenerative disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00406029 Background | Nov 2006 → Oct 2008 | Parkinson disease, movement disorder, neurodegenerative disease | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2/3 | NCT04000919 Comparator | Jun 2019 → Jun 2023 | spinal cord injury | Jessica M D'Amico | Suspended | No outcome recorded |
| Phase 3 | NCT01646255 Background | Jul 2012 → Oct 2014 | Parkinson disease | UCB Pharma | Completed | Met primary |
| Phase 3 | NCT01504178 Comparator | May 2011 → Dec 2015 | Parkinson disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT01770145 Background | Dec 2012 → Apr 2014 | Parkinson disease, akinetopsia, movement disorder | Supernus Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01494532 Background | Apr 2012 → Nov 2014 | Parkinson disease | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT01361373 Comparator | May 2010 → May 2012 | dystonic disorder | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00485069 Background | Jun 2007 → Dec 2009 | Parkinson disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00373087 Background | Oct 2006 → Nov 2009 | Parkinson disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Dopa | “This is a monocentric randomized blinded cross-over study comparing acute challenge of L-dopa + placebo versus L-dopa + 200 mg entacapone, in Parkinson's disease patients with...” NCT00373087 ↗25“a dopamine precursor L-Dopa to increase CNS dopamine transmission.” NCT03754062 ↗ “L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)” NCT04000919 ↗ “Ropinirole as adjunctive therapy with L-dopa” NCT01494532 ↗ |
| Known as | 3,4-dihydroxy-L-phenylalanine | “Here we show that, during instrumental learning, the magnitude of reward prediction error expressed in the striatum is modulated by the administration of drugs enhancing...” PMID 16929307 ↗ Aug 2006 |
| Known as | L-3,4-dihydroxyphenylalanine | “187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain...” NCT03891095 ↗1“The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals...” NCT04000919 ↗ |
| Known as | levodopa | “L-dopa (levodopa), used in dopaminergic disorders, has shown beneficial effects in a CTNNB1 patient.” NCT07614126 ↗ |
| Modality | Peptide | “L-DOPA, a neuropeptide” NCT03891095 ↗ |
| Route | Oral | “hard gelatin capsule to be taken bid for six weeks” NCT01092065 ↗ |